Rioto Suzuki1, Yutaka Nakamura2, Shinji Chiba3, Tomoki Mizuno4, Kazuyuki Abe5, Yosuke Horii6, Hiromi Nagashima7, Tatsuo Tanita8, Kohei Yamauchi9. 1. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 0208505, Japan. Electronic address: m38_riotos@yahoo.co.jp. 2. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 0208505, Japan. Electronic address: ICB75097@nifty.com. 3. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 0208505, Japan. Electronic address: shinji6311chiba@yahoo.co.jp. 4. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 0208505, Japan. Electronic address: tmizuno1004@gmail.com. 5. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 0208505, Japan. Electronic address: anything3137@gmail.com. 6. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 0208505, Japan. Electronic address: m06092yh@jichi.ac.jp. 7. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 0208505, Japan. Electronic address: all-checker1983@m7.dion.ne.jp. 8. Department of Thoracic Surgery, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 0208505, Japan. Electronic address: ttanita@iwate-med.ac.jp. 9. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1 Uchimaru, Morioka, 0208505, Japan. Electronic address: kyamauch@iwate-med.ac.jp.
Abstract
BACKGROUND: Statin use in individuals with chronic obstructive pulmonary disease (COPD) with coexisting cardiovascular disease is associated with a reduced risk of exacerbations. The mechanisms by which statin plays a role in the pathophysiology of COPD have not been defined. To explore the mechanisms involved, we investigated the effect of statin on endothelial cell function, especially endothelial cell tight junctions. METHOD: We primarily assessed whether pitavastatin could help mitigate the development of emphysema induced by continuous cigarette smoking (CS) exposure. We also investigated the activation of liver kinase B1 (LKB1)/AMP-activated protein kinase (AMPK) signaling, which plays a role in maintaining endothelial functions, important tight junction proteins, zonula occludens (ZO)-1 and claudin-5 expression, and lung microvascular endothelial cell permeability. RESULTS: We found that pitavastatin prevented the CS-induced decrease in angiomotin-like protein 1 (AmotL1)-positive vessels via the activation of LKB1/AMPK signaling and IFN-γ-induced hyperpermeability of cultured human lung microvascular endothelial cells by maintaining the levels of AmotL1, ZO-1, and claudin-5 expression at the tight junctions. CONCLUSION: Our results indicate that the maintenance of lung microvascular endothelial cells by pitavastatin prevents tight junction protein dysfunctions induced by CS. These findings may ultimately lead to new and novel therapeutic targets for patients with COPD.
BACKGROUND: Statin use in individuals with chronic obstructive pulmonary disease (COPD) with coexisting cardiovascular disease is associated with a reduced risk of exacerbations. The mechanisms by which statin plays a role in the pathophysiology of COPD have not been defined. To explore the mechanisms involved, we investigated the effect of statin on endothelial cell function, especially endothelial cell tight junctions. METHOD: We primarily assessed whether pitavastatin could help mitigate the development of emphysema induced by continuous cigarette smoking (CS) exposure. We also investigated the activation of liver kinase B1 (LKB1)/AMP-activated protein kinase (AMPK) signaling, which plays a role in maintaining endothelial functions, important tight junction proteins, zonula occludens (ZO)-1 and claudin-5 expression, and lung microvascular endothelial cell permeability. RESULTS: We found that pitavastatin prevented the CS-induced decrease in angiomotin-like protein 1 (AmotL1)-positive vessels via the activation of LKB1/AMPK signaling and IFN-γ-induced hyperpermeability of cultured human lung microvascular endothelial cells by maintaining the levels of AmotL1, ZO-1, and claudin-5 expression at the tight junctions. CONCLUSION: Our results indicate that the maintenance of lung microvascular endothelial cells by pitavastatin prevents tight junction protein dysfunctions induced by CS. These findings may ultimately lead to new and novel therapeutic targets for patients with COPD.
Authors: Andrey Ziyatdinov; Margaret M Parker; Amaury Vaysse; Terri H Beaty; Peter Kraft; Michael H Cho; Hugues Aschard Journal: Eur J Hum Genet Date: 2019-12-13 Impact factor: 4.246
Authors: Shinhee Park; Pureun-Haneul Lee; Ae Rin Baek; Jong Sook Park; Junehyuk Lee; Sung-Woo Park; Do Jin Kim; An-Soo Jang Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-10-05
Authors: Byeong Gon Kim; Pureun Haneul Lee; Sun Hye Lee; Ae Rin Baek; Jong Sook Park; Junehyuk Lee; Sung Woo Park; Do Jin Kim; Choon Sik Park; An Soo Jang Journal: Allergy Asthma Immunol Res Date: 2018-09 Impact factor: 5.764